Concomitant Use of Dayvigo and Verapamil
Avoid concomitant use of Dayvigo (lemborexant) with verapamil, as verapamil is a moderate CYP3A inhibitor that significantly increases lemborexant exposure and may increase the risk of adverse reactions including excessive somnolence, sleep paralysis, and complex sleep behaviors. 1
Drug Interaction Mechanism
Verapamil is specifically listed as a moderate CYP3A inhibitor in the FDA label for Dayvigo, and the official prescribing information explicitly states to "avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors" 1
Lemborexant is eliminated primarily through CYP3A metabolism, making it highly susceptible to interactions with CYP3A inhibitors 2
PBPK modeling demonstrates that moderate CYP3A inhibitors like verapamil produce moderate increases in lemborexant exposure, which translates to increased risk of dose-dependent adverse effects 2
Clinical Implications and Safety Concerns
The most concerning adverse reactions with increased lemborexant exposure include:
These risks are dose-dependent and would be amplified by the increased drug exposure caused by verapamil's CYP3A inhibition 1
Alternative Management Strategies
If both medications are deemed necessary, consider alternative calcium channel blockers that do not inhibit CYP3A, such as amlodipine, which has no significant CYP3A inhibitory effects 3
Alternatively, consider non-CYP3A-metabolized sleep medications if verapamil therapy cannot be changed 2
In countries where a 2.5 mg lemborexant dose is approved, this lower dose might be considered with moderate CYP3A inhibitors, though this is not FDA-approved in the United States 2
Important Caveat
The FDA label makes no exceptions for dose adjustment with moderate CYP3A inhibitors like verapamil—the recommendation is complete avoidance, unlike with weak CYP3A inhibitors where a maximum 5 mg dose is permitted 1